---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347853"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-08-13T11:05:15+00:00"
generated_at: "2026-08-13T11:10:21.312286+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Olema Pharmaceuticals appoints Jason O'Byrne as CFO, effective Aug 11, 2026

## Summary
- O'Byrne previously CFO at Vir Biotechnology (2024-2026) and Caribou Biosciences (2021-2024); joins Olema from Vir.
- Compensation: $545,000 base salary, 45% target bonus, $250,000 sign-on bonus plus $100,000 at 1-year anniversary.
- Granted option for 650,000 shares under 2022 Inducement Plan, vesting over 4 years (25% at 1-year, then monthly).
- Company cites upcoming pivotal OPERA-01 data and first potential commercial launch; highlights palazestrant and OP-3136.

## SEC filing metadata
- accession: 0001193125-26-347853
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-08-13T11:05:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/0001193125-26-347853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/olma-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347853
- JSON: https://secwatch.observer/filing/0001193125-26-347853.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.